Live
CellRational discovery of therapeutic PAK1 allosteric activatorsCellA 3D morphogenetic blueprint for metastatic outgrowth in breast cancerCellArbitrium phages can manipulate each other’s lysis/lysogeny decisionsCellSulfur partitioning from cysteine controls T cell proliferation and effector functionCellPhages communicate across species to shape microbial ecosystemsFierceBiotechFDA extends review of Orca Bio’s novel cell therapy for blood cancersFierceBiotech‘There isn't as much meat left to cut’: Biopharma layoffs maintain slowdown in Q1FierceBiotechOric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock downFierceBiotechAlzheimer's-focused Korsana to use Cyclerion reverse merger to go publicEndpoints NewsLilly wins approval of anti-obesity pill orforglipron, setting up new battle with NovoEndpoints NewsAmgen, Zai Lab team up on DLL3; Janux gets $35M milestone paymentEndpoints NewsParagon offshoot Korsana to go public in reverse merger for Alzheimer's work
FierceBiotech Apr 1, 2026

Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down

Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down

Original
Body unavailable. Use the original source.

Directory

59 All